Relmada Therapeutics Inc.

0.29
-0.01 (-4.32%)
At close: Apr 03, 2025, 3:59 PM
0.29
0.79%
After-hours: Apr 03, 2025, 04:42 PM EDT
-4.32%
Bid 0.28
Market Cap 9.47M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -2.65
PE Ratio (ttm) -0.11
Forward PE -0.27
Analyst Hold
Ask 0.29
Volume 349,298
Avg. Volume (20D) 976,970
Open 0.29
Previous Close 0.30
Day's Range 0.28 - 0.33
52-Week Range 0.24 - 5.09
Beta 0.65

About RLMD

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder ...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 20, 2014
Employees 20
Stock Exchange NASDAQ
Ticker Symbol RLMD
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for RLMD stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 250.63% from the latest price.

Stock Forecasts
4 months ago
-9.03%
Relmada Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
6 months ago
+13.53%
Relmada Therapeutics shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.5 to $13.